一、修订《公司章程》及取消监事会情况 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司章程 指引》及中国证券监督管理委员会发布的《关于新配套制度规则实施相关过渡安 排》等法律法规、规范性文件的最新规定，拟对《公司章程》中的相关条款进行 修订和完善。本次公司章程修订的具体情况详见附表，修订后的《公司章程》详 见本公告附件。 本次《公司章程》修订生效后，公司将不再设置监事会或监事，监事会的职 权由董事会审计委员会行使，公司《监事会议事规则》等监事会相关制度相应废 止。 证券代码：600789 证券简称：鲁抗医药 公告编号：2025-041 山东鲁抗医药股份有限公司 关于取消监事会、修订《公司章程》及修订、制定和废止 部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 的第十一届董事会第八次会议审议并通过《关于取消监事会及修订〈公司章程〉 的议案》《关于修订、制定和废止部分治理制度的议案》,现就相关情况公告如下： 本 ...

Core Viewpoint - The company reported a slight increase in revenue and profit for the first half of the year, indicating stable performance despite market conditions [1] Financial Performance - The company achieved operating revenue of 946 million yuan in the first half of the year, representing a year-on-year growth of 1.41% [1] - The net profit attributable to shareholders was 76.1465 million yuan, showing a year-on-year increase of 6.82% [1] - The basic earnings per share were reported at 0.47 yuan [1]

Core Viewpoint - The North Exchange 50 index reached a historical high of 1637.50 points on August 19, 2025, marking the first time it surpassed the 1600-point threshold, with a cumulative increase of approximately 12.21% in August 2025 [1][2]. Company Summaries HaiNeng Technology - HaiNeng Technology reported a total revenue of approximately 1.36 million yuan for the first half of 2025, representing a year-on-year growth of 34.87%, and a net profit of approximately 547.15 thousand yuan, marking a year-on-year increase of 139.03% [3][6]. - The company specializes in the manufacturing of scientific instruments, with a gross margin of 75.45%. The organic element analysis series contributed over 30% of its revenue, amounting to approximately 0.46 billion yuan [3][5]. - HaiNeng Technology is developing an instrument control system based on the domestic "Hongmeng" operating system, with initial tests conducted in June 2025 and plans for broader implementation within the year [6][7]. GeBiJia - GeBiJia, a national-level specialized "little giant" enterprise, focuses on the research, manufacturing, and sales of optical glass and special functional glass, with a total revenue of approximately 5.66 billion yuan in 2024 [10][11]. - The company's optical glass products accounted for about 66% of its revenue, while revenue from special functional glass products saw a significant decline of 67.63% [10][11]. - GeBiJia's products are widely used in various applications, including security monitoring, consumer electronics, and automotive lenses, with a focus on the consumer electronics sector for future development [10][12]. Market Performance - Both HaiNeng Technology and GeBiJia experienced significant stock price increases in August 2025, with HaiNeng Technology's stock reaching a historical high of 46.98 yuan and a trading volume of 11.22 billion yuan [7][9]. - GeBiJia's stock also saw a notable increase, with a cumulative price deviation of 44.54% from August 15 to August 18, 2025 [13].

Core Viewpoint - Shandong Lukang Pharmaceutical Co., Ltd. has received approval from the Shanghai Stock Exchange for its application to issue shares to specific targets, pending final registration approval from the China Securities Regulatory Commission (CSRC) [1] Group 1 - The company received the Shanghai Stock Exchange's review opinion on August 20, 2025, confirming that the application meets the issuance conditions, listing conditions, and information disclosure requirements [1] - The company must obtain approval from the CSRC before proceeding with the issuance of shares, and the timing and outcome of this approval remain uncertain [1] - The company commits to timely information disclosure in accordance with relevant laws and regulations regarding the issuance of shares to specific targets [1]

Core Viewpoint - Luant Pharmaceutical (600789.SH) has received approval from the Shanghai Stock Exchange for its application to issue shares to specific investors, pending final approval from the China Securities Regulatory Commission (CSRC) [1] Fundraising Details - The total amount to be raised from the issuance is not exceeding 120 million yuan, which will be allocated to projects including high-end formulation intelligent manufacturing workshop, bio-pesticide base construction, new drug research and development, and working capital [1][2] - The total investment for the projects is approximately 128.42 million yuan, with specific allocations as follows: - High-end formulation intelligent manufacturing workshop: 44.24 million yuan - Bio-pesticide base construction: 43.22 million yuan - New drug research and development: 20.97 million yuan - Working capital: 20 million yuan [2] Issuance Participants - The issuance will involve no more than 35 qualified investors, including Hualu Group, which plans to subscribe for 23.81% of the shares issued, amounting to no more than 64,201,417 shares [3] - Other potential investors include securities investment fund management companies, securities firms, financial companies, asset management companies, insurance institutions, trust companies, and qualified foreign institutional investors [2] Shareholding Structure - As of September 30, 2024, the total share capital of the company is 898,669,632 shares, with Hualu Group holding 20.69% and Hualu Investment holding 3.13% [5] - Post-issuance, Hualu Group's shareholding will remain unchanged, ensuring that the control of the company does not change [5] Regulatory Compliance - The issuance is subject to compliance with relevant laws and regulations, and the company will fulfill its information disclosure obligations as required [1][4]

登录新浪财经APP 搜索【信披】查看更多考评等级 山东鲁抗医药股份有限公司（以下简称"公司"）于2025年8月20日收到上海证券交易所出具的《关于山 东鲁抗医药股份有限公司向特定对象发行股票的交易所审核意见》，具体审核意见如下： "山东鲁抗医药股份有限公司向特定对象发行股票申请符合发行条件、上市条件和信息披露要求。本所 将在收到你公司申请文件后提交中国证监会注册。" 公司本次向特定对象发行股票事项尚需获得中国证券监督管理委员会（以下 简称"中国证监会"）同意 注册后方可实施，最终能否获得中国证监会同意注册 的决定及其时间尚存在不确定性。公司将根据进 展情况，严格按照上市公司向特 定对象发行股票相关法律法规的规定和要求及时履行信息披露义务， 敬请投资者 注意。 特此公告。 关于向特定对象发行股票申请 获得上海证券交易所审核通过的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司董事会 证券代码：600789 证券简称：鲁抗医药 公告编号：2025一038 山东鲁抗医药股份有限公司 2025年8月21日 ...

（文章来源：证券日报） 证券日报网讯 8月20日晚间，鲁抗医药发布公告称，山东鲁抗医药股份有限公司（以下简称"公司"）于 2025年8月20日收到上海证券交易所出具的《关于山东鲁抗医药股份有限公司向特定对象发行股票的交 易所审核意见》，具体审核意见如下："山东鲁抗医药股份有限公司向特定对象发行股票申请符合发行 条件、上市条件和信息披露要求。本所将在收到你公司申请文件后提交中国证监会注册。" ...

山东鲁抗医药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日收到上 海证券交易所出具的《关于山东鲁抗医药股份有限公司向特定对象发行股票的交 易所审核意见》，具体审核意见如下： "山东鲁抗医药股份有限公司向特定对象发行股票申请符合发行条件、上市 条件和信息披露要求。本所将在收到你公司申请文件后提交中国证监会注册。" 证券代码：600789 证券简称：鲁抗医药 公告编号：2025—038 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请 获得上海证券交易所审核通过的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司本次向特定对象发行股票事项尚需获得中国证券监督管理委员会（以下 简称"中国证监会"）同意注册后方可实施，最终能否获得中国证监会同意注册 的决定及其时间尚存在不确定性。公司将根据进展情况，严格按照上市公司向特 定对象发行股票相关法律法规的规定和要求及时履行信息披露义务，敬请投资者 注意。 特此公告。 山东鲁抗医药股份有限公司董事会 2025 年 8 月 21 日 ...

Group 1 - Yara International's chairman was arrested for embezzlement and abuse of power, but the company's operations remain normal and control has not changed [2][9] - Tenglong Co., Ltd. reported that it has small-scale products indirectly applied in data center/server liquid cooling and energy storage liquid cooling, with limited revenue impact [3] - Xianda Co., Ltd. achieved a net profit of 136 million yuan in the first half of 2025, a year-on-year increase of 2561.58%, driven by rising product prices and new product launches [4][25] Group 2 - Jifeng Technology announced a collective resignation of its board members, leading to a change in control [5] - Xiling Information's controlling shareholder is under investigation, but the company's control remains unchanged [6] - Chitianhua's subsidiary plans a scheduled maintenance shutdown for 35 days, which will not affect annual production targets [7] Group 3 - Shentong Express reported a revenue of 4.287 billion yuan in July 2025, a year-on-year increase of 9.95% [8] - Tianyu Digital's board member was arrested for embezzlement, but the company maintains normal operations [9] - Shaanxi Natural Gas's controlling shareholder plans to transfer 13% of its shares, affecting the ownership structure [9] Group 4 - Kesheng Technology's actual controller is under investigation, but the company's operations remain normal [10] - Dazhu CNC reported a net profit of 263 million yuan in the first half of 2025, a year-on-year increase of 83.82% [11] - Jinli Permanent Magnet's net profit increased by 155% year-on-year, with significant sales in the new energy vehicle sector [12] Group 5 - China Shenhua's expansion project for the Wanzhou power plant has been approved with a total investment of 6.655 billion yuan [13] - Wanfu Biology reported a net profit of 189 million yuan in the first half of 2025, a year-on-year decrease of 46.82% [13] - Round Express reported a revenue increase of 12.08% in July 2025 [13] Group 6 - Soft Control Co., Ltd. reported a net profit decrease of 23.84% in the first half of 2025 [21] - Jiangte Electric's subsidiary has completed maintenance and will resume production [21] - Blue Ocean Huaten reported a net profit increase of 159.83% in the first half of 2025 [22]

证券代码：600789 证券简称：鲁抗医药 公告编号：2025—037 一、药品基本信息 药品名称：注射用 CIGB-814 剂型：注射剂 注册分类：化学药品 1 类 适应症：类风湿性关节炎 山东鲁抗医药股份有限公司 关于注射用 CIGB-814 的 I 期临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司（以下简称"公司"）于 2024 年 11 月收到国家药 品监督管理局核准签发的注射用 CIGB-814 的《药物临床试验批准通知书》，具 体内容详见公司于 2024 年 11 月 12 日在指定信息披露媒体披露的《山东鲁抗医 药股份有限公司关于获得药物临床试验批准通知书的公告》（公告编号： 2024-060）。 注射用 CIGB-814 已经启动 I 期临床试验，并于近日完成首例受试者入组。 现将相关情况公告如下： 成临床试验方可进行药品注册上市许可申请。 由于药物研发的特殊性，药物从临床试验到投产的周期长，环节多，易受不 可预测的因素影响，在临床试验中可能因为各种潜 ...